Eisai

News

CMS update on Alzheimer's coverage raises questions

The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they

News

NHS will roll out ‘lifeline’ endometrial cancer regimen

The NHS has agreed a pair of commercial deals with Merck & Co/MSD and Eisai that will allow hundreds of women with advanced endometrial cancer to get access to life-ex

News

Five takeaways from the new donanemab data

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg

News

Donanemab data “strongest yet” in Alzheimer’s

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t

News

FDA advisors will look at full Leqembi approval in June

The FDA has convened a meeting of an advisory committee in June to consider the bid by Eisai and Biogen to convert their accelerated approval of Alzheimer’s disease therap

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

CMS update on Alzheimer's coverage raises questions

NHS will roll out ‘lifeline’ endometrial cancer regimen

Five takeaways from the new donanemab data

Donanemab data “strongest yet” in Alzheimer’s

FDA advisors will look at full Leqembi approval in June

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks